After hours: 4:17PM EDT
|Bid||17.80 x 800|
|Ask||17.81 x 800|
|Day's Range||17.36 - 18.14|
|52 Week Range||6.81 - 26.77|
|Beta (3Y Monthly)||2.79|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 12, 2018 - Feb 16, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||26.96|
Invitae (NVTA) is a genetic information company with a $1.6 billion market cap that's working to bring comprehensive genetic information into mainstream medical practice, notes Tyler Laundon, editor of Cabot Small Cap Confidential.
SAN FRANCISCO , May 15, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), the leader in advanced medical genetics, today announced that Sean George , co-founder and chief executive officer of Invitae, ...
While we can research the family tree for these health issues, it’s been difficult to know for sure what could happen — until now. Because of breakthroughs in human genome mapping, we can now get a clear line of sight on what diseases are coming our way — and the insights are only getting better.
Invitae (NVTA) delivered earnings and revenue surprises of -2.17% and -12.85%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the San Francisco-based company said it had a loss of 47 cents. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
Invitae Corp. shares plummeted more than 10% in the extended session Tuesday after the company missed sales estimates. The company reported first-quarter net losses of $37.7 million, or 47 cents a share, versus losses of $36.1 million, or 66 cents a share, in the year-ago period. Revenue rose to $40.6 million from $27.7 million in the year-ago period. Analysts surveyed by FactSet had estimated earnings of 47 cents a share on revenue of $47.2 million. For the second quarter, analysts model earnings of 44 cents a share on sales of $54.4 million. Invitae stock gained 310% in the past year, with the S&P 500 index rising 9.7%.
-- On track to deliver more than 500,000 test samples and more than $220 million in revenue in 2019 -- -- Signed eight new biopharma partnerships in the quarter, expanding the breadth of the genome network ...
Amid an overall market correction, many stocks that smart money investors were collectively bullish on tanked during the fourth quarter. Among them, Amazon and Netflix ranked among the top 30 picks and both lost more than 25%. Facebook, which was the second most popular stock, lost 20% amid uncertainty regarding the interest rates and tech […]
SAN FRANCISCO, May 3, 2019 /PRNewswire/ -- Researchers from Invitae (NVTA), a leading genetics company, will present a study of more than 6,500 patients with uterine cancer showing that genetic testing provided more than 80 percent of patients with information that made them eligible for precision medicine therapies. The study also highlighted the importance of multigene panel testing versus traditional, limited approaches and was presented this week at the 2019 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting. "Genetic testing for uterine carcinoma has traditionally been limited to a very targeted number of genes that have an association with uterine cancer," said Robert Nussbaum, M.D., chief medical officer of Invitae and one of the authors of the study. "This study revealed that such limited testing misses other cancer genes that are actionable for the prevention, early detection, and treatment of malignancies.
Invitae (NVTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN FRANCISCO, April 23, 2019 /PRNewswire/ -- Invitae Corporation (NVTA), a leading genetics company, today announced that it will report its first quarter 2019 financial results on Tuesday, May 7, 2019 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. The dial-in numbers for the conference call are (866) 393-4306 for domestic callers and (734) 385-2616 for international callers, and the reservation number for both is 3435689. Invitae Corporation (NVTA) is a leading genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people.
Top-line growth and solid show by Population Health, Revenue Cycle and IT Works are likely to aid Cerner (CERN) in Q1. However, expected decline in bookings is likely to be a dampener.
It's the same action that we've had for much of this week. Stocks press lower near the open only to recover by lunch and push higher in the afternoon. The gains aren't remarkable, but the bulls' resilience is something to take note of. The sector rotation underway also remains astounding. On that note, let's look at a few must-see stock charts for Monday.Remember, the U.S. markets are closed tomorrow for Good Friday. Must-See Stock Charts for Monday 1: InvitaeInvestorPlace - Stock Market News, Stock Advice & Trading TipsAbove is the daily chart for Invitae (NASDAQ:NVTA) and below is the weekly. This morning on Twitter, I pointed out that NVTA could post a sweet bounce, but I didn't think it would be this vicious.Shares ripped off of the 10-week and 50-day moving averages, gaining almost 8% from today's lows. This is definitely one to watch next week to see if the momentum can continue.I would have loved to buy NVTA at $21, but over $22 and NVTA could be primed for more upside. Must-See Stock Charts for Monday 2: BlackstoneBlackstone (NYSE:BX) delivered a strong earnings report and announced it will switch from a partnership to a corporation. Anyone ever own BX before? I have and waiting for a K-1 form that doesn't usually come until April is a pain the you-know-what. Switching to a corporation will make sense for the business and potentially make its stock more attractive to investors. Plus it has a monster yield.Could that cause a further breakout? Perhaps. Over $38 is encouraging for more upside, with long-term uptrend resistance not playing a role until the $40s. Below $38 and bulls may need to let BX reset. Above and it's okay. Must-See Stock Charts for Monday 3: Canopy GrowthAn explosive couple of days have put Canopy Growth (NYSE:CGC) back on the radar. But if the strong rally on Wednesday and Thursday proved anything to me, it's how tough of resistance $38 is.I'm watching CGC next week to see if the stock can pierce this level. If it can, it would be very bullish to see CGC find $38 as support. As long as it holds $44, CGC should be good on the long side. Must-See Stock Charts for Monday 4: Union PacificBetter than expected earnings propelled Union Pacific (NYSE:UNP) to new 52-weeks high on Thursday. There sure are a lot of bearish calls out there despite so many names hitting new annual highs.Anyway, as long as UNP stock holds $160 next week, the bull case still looks strong. A pullback to the 10-week moving average that holds as support can be bought, while a run to channel resistance is possible over the intermediate term. Must-See Stock Charts for Monday 5: PinterestThe Pinterest (NYSE:PINS) and Zoom (NASDAQ:ZM) IPOs got off to a much better start than Lyft (NASDAQ:LYFT) did, currently up 30% and 75% on the day, respectively.For investors, there a lot less volatile plays out there than these fresh IPOs. But if you have to play them, investors at least have the IPO day range to work with. A red-to-green open on Monday could draw in more buyers for PINS, while a push through the highs could ad even more momentum to the name. * The Jobs Report Isn't an Effective Metric for the U.S. Economy If it's too short term for you, don't have any regrets about giving it more time to base. (Here are 13 things to know about the Pinterest IPO).Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long NVTA. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Dividend Stocks Perfect for Retirees * 7 Reasons the Stock Market Rally Isn't Over Yet * 10 S&P 500 Stocks to Weather the Earnings Storm Compare Brokers The post 5 Must-See Stock Charts for Monday: CGC, PINS, NVTA, UNP, BX appeared first on InvestorPlace.
Investors are always looking for growth in small-cap stocks like Invitae Corporation (NYSE:NVTA), with a market cap of US$2.2b. However, an important fact which most ignore is: how financially healthy is the business...
Stock investors seeking even bigger returns than the 2019 bull rally might look at five ETFs that have already gained at least 40% year-to-date, approaching triple the 15% pace of the S&P 500. The winners ...